News
People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.
The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results